Alkermes Plc (ALKS) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Alkermes Plc stock $48.99, price $45.90, upside +6.7%, quality 68 out of 100. Rating: fairly valued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $21.47 – $55.22 · fair‑value band $36.75 – $59.40 · the $45.90 price screens below the $48.99 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Follow Alkermes in your weekly email
Every Wednesday you see whether Alkermes is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
Show moreShow less
The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients.
The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.
Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Stock analysis
Alkermes Plc (ALKS) currently trades at $45.90, while our model-based Fair Value estimate is $48.99, so the stock looks roughly fairly valued today (gap 6.3%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $59.19 per share, and 8 of the 24 models we run sit above the $45.90 price.
Bear case: the Asset-Based group reads lowest at $7.25, and 16 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $36.75 (bear) to $59.40 (bull), the price of $45.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Alkermes Plc reported revenue of $1.5B in FY2025 versus $1.2B in FY2021, a compound +5.9%/yr. Reported net income was $242M in FY2025.
Key figures
Market cap $7.6B Mid · P/S ratio 4.27 · EPS (TTM) $−0.0100 · Net margin 0.0% · Return on equity 0.0% · Return on assets (EBIT) 10.9% (5-year average) · Operating margin 13.8% · Revenue (TTM) $1.8B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 69% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 7%, ALKS screens cheaper than that median.
Fair Value models
Bear$36.75Fair Value $48.99Bull$59.40
Price $45.90 · Upside +6.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 6 officers or directors sold shares worth $5.7M and none bought.
SaleDavid Joseph GaffinEVP, CLO, Alkermes, Inc.9× since Mar 2, 2026: 20,341 shares, avg. $40.77$829,288Nov 3, 202610b5-1 plan
SaleCraig C. HopkinsonEVP R&D, Chief Medical Officer12× since Dec 1, 2025: 88,748 shares, avg. $38.12$3.4MSep 1, 202610b5-1 plan
SaleChristian Todd NicholsSVP, Chief Commercial Officer2× since Mar 2, 2026: 13,576 shares, avg. $40.73$552,969Aug 17, 202610b5-1 plan
Salenancy lynn snyderman MDDirector44,472 shares at $50.35$2.2MAug 3, 2026
SaleChristopher I WrightDirector2,000 shares at $45.10$90,200Jun 12, 202610b5-1 plan
SaleSamuel Joseph ParisiVP, Finance (Interim PAO)2× since Mar 2, 2026: 23,107 shares, avg. $38.46$888,760May 29, 2026
SaleShane CookeDirector61,200 shares at $34.57$2.1MFeb 2, 202610b5-1 plan
Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−5.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Start year 2020 (pandemic). Over 10 years: +8.9% a year
Revenue growth 34 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−11.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−11.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−11% → 17%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.2%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+8.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −2.6% a year for the price and +5.6% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Negative
Recent news coverage is more negative than average.
AI conclusion: The established specialty CNS portfolio anchors operations with solid margins, while thin public signals on moat factors constrain stronger conviction in quality.
Main risk: Takeda’s approved Orzeyful and other orexin agonists from Centessa and Harmony could capture narcolepsy and ADHD market share from Alkermes’ alixorexton and ALKS 7290, limiting uptake and pressuring prices or margins.
Bull case: Alkermes could leverage once-daily dosing and expansion into ADHD and MDD to differentiate alixorexton from twice-daily rivals and grow the orexin platform beyond legacy products.
Bear case: If Takeda and other orexin agonists dominate approvals and uptake while Vivitrol generics erode legacy sales, the company’s CNS portfolio and new pipeline could face sustained revenue pressure without offsetting growth.
Alkermes has applied lessons from its narcolepsy orexin program to test ALKS 7290 in ADHD, where phase 1b data showed rapid symptom relief and good tolerability. The established specialty CNS portfolio anchors the business while this mechanism moves into a new area. Will the larger phase 2 trial confirm broader utility for orexin agonists or confirm the limits of repurposing sleep-focused science?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score68 · Top 25%
Fair Value upside+6.7% · Above median
Profitability
Return on assets9.6% · Top 25%
Net margin (12 months)0.0% · Bottom 25%
Operating margin (12 months)13.8% · Above median
Growth and dividend
Revenue growth (quarter YoY)21.8% · Top 25%
Balance sheet
Debt / equity0.16× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B4.20× · Priciest 25%
P/S (12 months)4.36× · Priciest 25%
Price / free cash flow (fiscal year)15.9× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Alkermes Plc Fair Value". https://www.fairvalue-calculator.com/stock/ALKS
Frequently asked questions
Is Alkermes Plc (ALKS) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $48.99 versus a price of $45.90, about +7% upside (fairly valued).
What is the fair value of ALKS?
Our model-based fair value for Alkermes Plc is $48.99 (as of Nov 6, 2026), built from audited fundamentals. The current price: $45.90.
What is the quality score of ALKS?
Alkermes Plc has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alkermes Plc (ALKS)?
Our model-based price target is the fair value of $48.99 (as of Nov 6, 2026) from 24 valuation models. Cautious scenario $36.75, optimistic scenario $59.40. It is a calculation from audited fundamentals, not an analyst target.
What is the Alkermes Plc stock forecast for 2026?
Our models put fair value at $48.99, about +7% upside versus a price of $45.90 (fairly valued). Cautious scenario $36.75, optimistic scenario $59.40. The calculation is refreshed regularly with new filings.
What is the revenue of Alkermes Plc (ALKS)?
Alkermes Plc reported trailing-twelve-month revenue of about $1.8B (latest available figure, as of Nov 6, 2026).
What growth is priced into Alkermes Plc (ALKS)?
For today's price to be fair in a discounted-cash-flow model, Alkermes Plc would have to grow free cash flow by -0.2 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.3 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of ALKS use?
Our models discount Alkermes Plc at 8.5 %: a base by market capitalisation (mid), damped by beta 0.23, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Alkermes Plc that is -0.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Alkermes Plc (ALKS) delivered so far?
Over the past 5 years revenue at Alkermes Plc grew +7.3 % a year. The price currently implies free-cash-flow growth of -0.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Alkermes Plc (ALKS) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Alkermes Plc (-0.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Alkermes Plc (ALKS)?
The free-cash-flow yield on the price is 6.28 %: that much free cash flow Alkermes Plc produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Alkermes Plc (ALKS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alkermes Plc it is $48.99 per share (as of Nov 6, 2026), against a price of $45.90. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Alkermes Plc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ALKS trades below its calculated fair value: price $45.90, fair value $48.99, a gap of about +7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALKS?
No. The price is what the market pays today ($45.90); the fair value is what the company's own numbers justify ($48.99). For Alkermes Plc the two are $3.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alkermes Plc worth?
The market values Alkermes Plc at about $7.6B (market capitalisation, as of Nov 6, 2026). Per share that is $45.90; our models calculate a fair value of $48.99 per share.
What do the bullish and bearish scenarios say about ALKS?
Our models span a range for Alkermes Plc: cautious scenario $36.75, base $48.99, optimistic $59.40 per share (as of Nov 6, 2026, price $45.90). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of ALKS?
The PEG ratio of Alkermes Plc is 1.96 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Alkermes Plc (ALKS)?
Balance-sheet figures for Alkermes Plc (as of Nov 6, 2026): return on equity 0.0%, debt of 0.16 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is ALKS from its 52-week high?
Alkermes Plc trades at $45.90, about 17% below its 52-week high of $55.22 and 69% above the low of $27.20 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $48.99 is for.
Which stocks are comparable to Alkermes Plc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alkermes Plc stock attractive at the current price?
The data as of Nov 6, 2026: price $45.90, calculated fair value $48.99 (+7%), Quality Score 68/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALKS calculated?
We run Alkermes Plc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $48.99 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Alkermes Plc currently trades 6% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alkermes Plc (ALKS)?
The closing price on Nov 6, 2026 was $45.90. Our model-based fair value is $48.99, about +7% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alkermes Plc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Alkermes Plc
How large is the market capitalisation of Alkermes Plc (ALKS)?
The market capitalisation of Alkermes Plc is $7.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Alkermes Plc (ALKS)?
The price-to-sales ratio of Alkermes Plc is 4.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Alkermes Plc (ALKS)?
Earnings per share at Alkermes Plc are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Alkermes Plc (ALKS)?
The net margin of Alkermes Plc is 0.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Alkermes Plc (ALKS)?
The return on equity (ROE) of Alkermes Plc is 0.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alkermes Plc (ALKS)?
On an EBIT basis the return on assets of Alkermes Plc is 10.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alkermes Plc (ALKS)?
The operating margin of Alkermes Plc is 13.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alkermes Plc (ALKS)?
Revenue at Alkermes Plc is growing +21.8% versus a year earlier (3y avg +9.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Alkermes Plc (ALKS)?
Earnings per share at Alkermes Plc are growing −81.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Alkermes Plc (ALKS) hold?
Alkermes Plc holds more cash than debt, $1.0B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Alkermes Plc in the live analysis
One click puts Alkermes Plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026